Non-Oncology Biologics and Biosimilars Market
完整報告名稱與涵蓋範圍
Non-Oncology Biologics and Biosimilars Market Size, Share & Trends Analysis Report By Drug Category (Monoclonal Antibody, Toxins, Fusion Proteins, Insulin, Hormones, Gene Therapy, and Others), By Application Type, By Product Type, By Region, And By Segment Forecasts, 2025-2034
報告摘要
The global Non-Oncology Biologics and Biosimilars Market is poised to progress at a compound annual growth rate of 22.0% throughout the 2025–2034 forecast period.
The Non-Oncology Biologics and Biosimilars sector involves key industry insights & findings from the report:
Advances in biotechnology enable the development of new biological drugs with improved efficacy, safety, and patient outcomes. This domain has witnessed notable transformation owing to technological breakthroughs and shifting healthcare dynamics.
The market's upward path is underpinned by escalating healthcare spending, technological evolution, and the escalating focus on personalized and precision-based approaches in healthcare.
From a segmentation standpoint, the market is categorized across multiple dimensions including product type, application, end-user, and geography, each exhibiting distinct growth patterns and opportunities.
Regional dynamics show North America and Europe as established hubs, with the Asia-Pacific region poised to deliver the strongest growth trajectory through the forecast period, underpinned by demographic shifts and policy support.
Industry participants are deploying a range of strategies—including partnerships, mergers, technological investments, and portfolio diversification—to consolidate their market standing.
This comprehensive research study delivers granular insights into market sizing, trend analysis, competitive benchmarking, and forward-looking projections to support strategic decision-making for industry participants and investors.
授權報價
| Single User PDF | $4,500 USD |
| Global Site License PDF | $9,500 USD |
目錄 Table of Contents
Chapter 1. Methodology and Scope
1.1. Research Methodology
1.2. Research Scope & Assumptions
Chapter 2. Executive Summary
Chapter 3. Global Non-oncology Biologics and Biosimilars Market Snapshot
Chapter 4. Global Non-oncology Biologics and Biosimilars Market Variables, Trends & Scope
4.1. Market Segmentation & Scope
4.2. Drivers
4.3. Challenges
4.4. Trends
4.5. Investment and Funding Analysis
4.6. Industry Analysis – Porter's Five Forces Analysis
4.7. Competitive Landscape & Market Share Analysis
4.8. Impact of Covid-19 Analysis
Chapter 5. Market Segmentation 1: By Drug Category Estimates & Trend Analysis
5.1. By Drug Category, & Market Share, 2024 & 2034
5.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2021 to 2034 for the following By Drug Category:
5.2.1. Monoclonal Antibody
5.2.2. Toxins
5.2.3. Fusion Proteins
5.2.4. Insulin
5.2.5. Hormones
5.2.6. Gene Therapy
5.2.7. Others
Chapter 6. Market Segmentation 2: By Application Type Estimates & Trend Analysis
6.1. By Application Type & Market Share, 2024 & 2034
6.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2021 to 2034 for the following By Application Type:
6.2.1. Dermatology
6.2.2. Endocrinology
6.2.3. Neurology
6.2.4. Immunology
6.2.5. Respiratory
6.2.6. Rheumatology
6.2.7. Ophthalmology
6.2.8. Others
Chapter 7. Market Segmentation 3: By Product Type Estimates & Trend Analysis
7.1. By Product Type & Market Share, 2024 & 2034
7.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2021 to 2034 for the following By Product Type:
7.2.1. Biologics
7.2.2. Biosimilars
Chapter 8. Non-oncology Biologics and Biosimilars Market Segmentation 4: Regional Estimates & Trend Analysis
8.1. North America
8.1.1. North America Non-oncology Biologics and Biosimilars Market revenue (US$ Million) estimates and forecasts By Drug Category, 2021-2034
8.1.2. North America Non-oncology Biologics and Biosimilars Market revenue (US$ Million) estimates and forecasts By Application Type, 2021-2034
8.1.3. North America Non-oncology Biologics and Biosimilars Market revenue (US$ Million) estimates and forecasts By Product Type, 2021-2034
8.1.4. North America Non-oncology Biologics and Biosimilars Market revenue (US$ Million) estimates and forecasts by country, 2021-2034
8.2. Europe
8.2.1. Europe Non-oncology Biologics and Biosimilars Market revenue (US$ Million) By Drug Category, 2021-2034
8.2.2. Europe Non-oncology Biologics and Biosimilars Market revenue (US$ Million) By Application Type, 2021-2034
8.2.3. Europe Non-oncology Biologics and Biosimilars Market revenue (US$ Million) By Product Type, 2021-2034
8.2.4. Europe Non-oncology Biologics and Biosimilars Market revenue (US$ Million) by country, 2021-2034
8.3. Asia Pacific
8.3.1. Asia Pacific Non-oncology Biologics and Biosimilars Market revenue (US$ Million) By Drug Category, 2021-2034
8.3.2. Asia Pacific Non-oncology Biologics and Biosimilars Market revenue (US$ Million) By Application Type, 2021-2034
8.3.3. Asia Pacific Non-oncology Biologics and Biosimilars Market revenue (US$ Million) By Product Type, 2021-2034
8.3.4. Asia Pacific Non-oncology Biologics and Biosimilars Market revenue (US$ Million) by country, 2021-2034
8.4. Latin America
8.4.1. Latin America Non-oncology Biologics and Biosimilars Market revenue (US$ Million) By Drug Category, (US$ Million) 2021-2034
8.4.2. Latin America Non-oncology Biologics and Biosimilars Market revenue (US$ Million) By Application Type, (US$ Million) 2021-2034
8.4.3. Latin America Non-oncology Biologics and Biosimilars Market revenue (US$ Million) By Product Type, (US$ Million) 2021-2034
8.4.4. Latin America Non-oncology Biologics and Biosimilars Market revenue (US$ Million) by country, 2021-2034
8.5. Middle East & Africa
8.5.1. Middle East & Africa Non-oncology Biologics and Biosimilars Market revenue (US$ Million) By Drug Category, (US$ Million) 2021-2034
8.5.2. Middle East & Africa Non-oncology Biologics and Biosimilars Market revenue (US$ Million) By Application Type, (US$ Million) 2021-2034
8.5.3. Middle East & Africa Non-oncology Biologics and Biosimilars Market revenue (US$ Million) By Product Type, (US$ Million) 2021-2034
8.5.4. Middle East & Africa Non-oncology Biologics and Biosimilars Market revenue (US$ Million) by country, 2021-2034
Chapter 9. Competitive Landscape
9.1. Major Mergers and Acquisitions/Strategic Alliances
9.2. Company Profiles
9.2.1. Accord Healthcare S.L.U.
9.2.2. Alvotech
9.2.3. Amgen
9.2.4. AYUMI Pharmaceutica
9.2.5. Biocon
9.2.6. Biogen
9.2.7. Biosimilar Collaborations Ireland Limited
9.2.8. Boeheringer Ingelheim
9.2.9. Celltrion
9.2.10. Cipla
9.2.11. Coherus Biosciences
9.2.12. Cordavis Ltd.
9.2.13. Epirus Biopharmaceuticals
9.2.14. Formycon AG
9.2.15. Fresenius Kabi
9.2.16. Glenmark Pharmaceuticals
9.2.17. Hanwha Chemical
9.2.18. Hetero
9.2.19. Innovent Biologics
9.2.20. Kyowa Hakko Kirin (Fujifilm Kyowa Kirin Biologics)
9.2.21. LG Chem
9.2.22. Lupin
9.2.23. Mabpharm
9.2.24. Merck
9.2.25. Midas Pharma GmbH
9.2.26. Mylan
9.2.27. Nichi-Iko Pharmaceutical
9.2.28. Organon & Co.
9.2.29. Pfizer
9.2.30. Qilu Pharma Spain S.L.
9.2.31. Ranbaxy Laboratories (now Sun Pharma)
9.2.32. Samsung Bioepis
9.2.33. Sandoz
9.2.34. Shanghai CP Guojian Pharmaceutical
9.2.35. Sorrento Therapeutics (partner)
9.2.36. STADA Arzneimittel AG
9.2.37. Sunshine Guojian Pharmaceutical
9.2.38. Synermore
9.2.39. Teva
9.2.40. Torrent Pharmaceuticals
9.2.41. YL Biologics
9.2.42. Zydus Cadila
9.2.43. Other prominent players
常見問題
這份報告可以先索取樣本嗎？
可以。建議購買前先申請樣本，提出申請後約 2 個工作天內提供，您可以先確認內容涵蓋範圍是否符合需求。
報告價格如何計算？
報告以美元標價，台幣報價依當日匯率換算並加計 5% 營業稅。不同授權版本（單人／多人／企業全站）價格不同，量子訊息會評估您的使用情境後提供最優惠報價。
下單後多久交付？如何付款？
一般 3–7 個工作天交付，實際依出版商狀況於下單前確認。收到報告確認無誤後開立台幣發票，30 天內電匯付款即可。
量子訊息有限公司為 InsightAce Analytic 在台灣的授權代理，提供報告購買、樣本申請與授權諮詢。電話 +886 2 7751 5192 ・ 聯絡我們